Piper Jaffray Companies set a $41.00 target price on Phibro Animal Health Corporation (NASDAQ:PAHC) in a report issued on Friday. The brokerage currently has a buy rating on the stock.

Several other analysts have also recently commented on the stock. Credit Suisse Group raised their price target on shares of Phibro Animal Health Corporation from $36.00 to $37.00 and gave the stock an outperform rating in a report on Thursday, August 31st. BidaskClub upgraded shares of Phibro Animal Health Corporation from a buy rating to a strong-buy rating in a report on Thursday, June 22nd. Finally, Bank of America Corporation restated an underperform rating and set a $33.00 price target on shares of Phibro Animal Health Corporation in a report on Wednesday, August 23rd. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The company currently has an average rating of Hold and a consensus price target of $33.00.

Phibro Animal Health Corporation (NASDAQ PAHC) opened at 37.45 on Friday. The firm has a market cap of $1.49 billion, a price-to-earnings ratio of 23.26 and a beta of 1.36. Phibro Animal Health Corporation has a 12 month low of $24.83 and a 12 month high of $40.25. The company’s 50-day moving average is $36.80 and its 200 day moving average is $34.71.

Phibro Animal Health Corporation (NASDAQ:PAHC) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.35 by $0.04. The business had revenue of $194.84 million during the quarter, compared to analysts’ expectations of $192.47 million. Phibro Animal Health Corporation had a net margin of 8.45% and a return on equity of 47.88%. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period last year, the company posted $0.32 earnings per share. On average, equities research analysts predict that Phibro Animal Health Corporation will post $1.56 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/09/piper-jaffray-companies-analysts-give-phibro-animal-health-corporation-pahc-a-41-00-price-target.html.

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 27th. Shareholders of record on Wednesday, September 6th were paid a $0.10 dividend. This represents a $0.40 dividend on an annualized basis and a yield of 1.07%. The ex-dividend date was Friday, September 1st. Phibro Animal Health Corporation’s dividend payout ratio (DPR) is presently 24.69%.

In other Phibro Animal Health Corporation news, insider Dean J. Warras sold 10,000 shares of Phibro Animal Health Corporation stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $35.70, for a total value of $357,000.00. Following the completion of the sale, the insider now directly owns 10,000 shares in the company, valued at $357,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Larry Lee Miller sold 21,439 shares of Phibro Animal Health Corporation stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $36.43, for a total transaction of $781,022.77. Following the completion of the sale, the chief operating officer now owns 15,891 shares of the company’s stock, valued at $578,909.13. The disclosure for this sale can be found here. Insiders sold 292,448 shares of company stock valued at $10,624,994 over the last quarter. Corporate insiders own 51.88% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Morgan Stanley lifted its stake in Phibro Animal Health Corporation by 1.7% in the first quarter. Morgan Stanley now owns 172,773 shares of the company’s stock valued at $4,855,000 after acquiring an additional 2,868 shares during the last quarter. Vanguard Group Inc. lifted its stake in Phibro Animal Health Corporation by 8.2% in the first quarter. Vanguard Group Inc. now owns 1,729,406 shares of the company’s stock valued at $48,597,000 after acquiring an additional 130,935 shares during the last quarter. Sawgrass Asset Management LLC acquired a new stake in Phibro Animal Health Corporation in the second quarter valued at approximately $410,000. Arizona State Retirement System lifted its stake in Phibro Animal Health Corporation by 2.1% in the first quarter. Arizona State Retirement System now owns 9,700 shares of the company’s stock valued at $273,000 after acquiring an additional 200 shares during the last quarter. Finally, Tudor Investment Corp ET AL lifted its stake in Phibro Animal Health Corporation by 66.2% in the first quarter. Tudor Investment Corp ET AL now owns 16,171 shares of the company’s stock valued at $454,000 after acquiring an additional 6,444 shares during the last quarter. Hedge funds and other institutional investors own 48.06% of the company’s stock.

About Phibro Animal Health Corporation

Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products.

Analyst Recommendations for Phibro Animal Health Corporation (NASDAQ:PAHC)

Receive News & Stock Ratings for Phibro Animal Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health Corporation and related stocks with our FREE daily email newsletter.